

2005

Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals

Gene D. Morse

University at Buffalo, SUNY

Susan Rosenkranz

Harvard University

Michael F. Para

Ohio State University - Main Campus

Yoninah Segal

Harvard University

Robin DiFrancesco

University at Buffalo, SUNY

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Morse, Gene D.; Rosenkranz, Susan; Para, Michael F.; Segal, Yoninah; DiFrancesco, Robin; Adams, Elizabeth; Brizz, Barbara; Yarasheski, Kevin E.; Reichman, Richard C.; and ACTG 5043 Protocol Team, "Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals." *Antimicrobial Agents and Chemotherapy*.49,8. 3373. (2005).
https://digitalcommons.wustl.edu/open_access_pubs/2361

Authors

Gene D. Morse, Susan Rosenkranz, Michael F. Para, Yoninah Segal, Robin DiFrancesco, Elizabeth Adams, Barbara Brizz, Kevin E. Yarasheski, Richard C. Reichman, and ACTG 5043 Protocol Team

Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals

Gene D. Morse, Susan Rosenkranz, Michael F. Para,
Yoninah Segal, Robin DiFrancesco, Elizabeth Adams,
Barbara Brizz, Kevin E. Yarasheski and Richard C.
Reichman
Antimicrob. Agents Chemother. 2005, 49(8):3373. DOI:
10.1128/AAC.49.8.3373-3381.2005.

Updated information and services can be found at:
<http://aac.asm.org/content/49/8/3373>

These include:

REFERENCES

This article cites 18 articles, 9 of which can be accessed free at:
<http://aac.asm.org/content/49/8/3373#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new
articles cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals

Gene D. Morse,^{1,7*} Susan Rosenkranz,^{2,7} Michael F. Para,^{3,7} Yoninah Segal,^{2,7}
Robin DiFrancesco,^{1,7} Elizabeth Adams,⁴ Barbara Brizz,^{7,8}
Kevin E. Yarasheski,^{5,7} Richard C. Reichman,^{6,7}
and the ACTG 5043 Protocol Team

University at Buffalo, SUNY, Amherst, New York¹; Harvard University, Boston, Massachusetts²; Ohio State University, Columbus, Ohio³; Division of AIDS, Bethesda, Maryland⁴; Washington University, St. Louis, Missouri⁵; University of Rochester, Rochester, New York⁶; Social and Scientific Systems, Inc., Silver Spring, Maryland⁷; and Adult AIDS Clinical Trials Group (ACTG), NIAID, Bethesda, Maryland⁸

Received 3 November 2004/Returned for modification 31 December 2004/Accepted 25 April 2005

Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV), indinavir (IDV), ritonavir (RTV), or saquinavir (SQV) is added. A PK study was conducted after the administration of single doses of APV (day 0). Subjects ($n = 56$) received 600 mg of EFV every 24 h (q24h) for 10 days and restarted APV with EFV for days 11 to 13 with a PK study on day 14. A second protease inhibitor (PI) (NFV, 1,250 mg, q12h; IDV, 1,200 mg, q12h; RTV, 100 mg, q12h; or SQV, 1,600 mg, q12h) was added to APV and EFV on day 15, and a PK study was conducted on day 21. Controls continued APV and EFV without a second PI. Among subjects, the APV areas under the curve (AUCs) on days 0, 14, and 21 were compared using the Wilcoxon signed-rank test. Ninety-percent confidence intervals around the geometric mean ratios (GMR) were calculated. APV AUCs were 46% to 61% lower (median percentage of AUC) with EFV (day 14 versus day 0; P values of <0.05). In the NFV, IDV, and RTV groups, day 21 APV AUCs with EFV were higher than AUCs for EFV alone. Ninety-percent confidence intervals around the GMR were 3.5 to 5.3 for NFV ($P < 0.001$), 2.8 to 4.5 for IDV ($P < 0.001$), and 7.8 to 11.5 for RTV ($P = 0.004$). Saquinavir modestly increased the APV AUCs (GMR, 1.0 to 1.4; $P = 0.106$). Control group AUCs were lower on day 21 compared to those on day 14 (GMR, 0.7 to 1.0; $P = 0.042$). African-American non-Hispanics had higher day 14 efavirenz AUCs than white non-Hispanics. We conclude that EFV lowered APV AUCs, but nelfinavir, indinavir, or ritonavir compensated for EFV induction.

The clinical use of antiretroviral regimens containing combinations of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PI) has become the accepted approach to therapy for human immunodeficiency virus (HIV) infection, especially for patients with multiple prior antiretroviral regimens (1, 29). This has led to the development of new antiretroviral treatments and clinical studies of three- and four-drug combinations as salvage regimens for antiviral-experienced patients. While these combination regimens are often guided by HIV-1 resistance assays, there are often incomplete pharmacokinetic (PK) data available to guide optimal dosing of dual protease inhibitors in an NNRTI-containing regimen.

Due to the complex nature of drug interactions (metabolic induction versus inhibition, efflux transporter interactions) and the desire to understand mechanisms underlying these drug interactions, Adult AIDS Clinical Trials Group (ACTG) protocol A5043 was developed to examine these interactions. At

the time A5043 was developed, the routine use of low-dose ritonavir (RTV) was not considered to be the standard of care, and the optimal approach to combining two PIs with efavirenz (EFV) was under investigation in ACTG 398. ACTG 398 utilized NNRTI-PI combinations similar to those of ACTG 5043 along with nucleoside analogs and reported ~30% antiviral responses in a group of PI-experienced patients (10). Another clinical study was conducted in a small group of patients with HIV-1 infection, examining two dosage regimens of reduced-dose ritonavir in combination with amprenavir (APV), efavirenz, and NRTIs, indicating that efavirenz induction could be offset by ritonavir (6). The pharmacologic objective of ACTG 5043 was to extend these studies and obtain additional data on indinavir (IDV)-, nelfinavir (NFV)-, and saquinavir (SQV)-containing regimens and their dosage requirements when combined with amprenavir and efavirenz in HIV-seronegative subjects. In addition, the inclusion of a control group that did not have a second PI added allowed for comparison against results obtained by continued efavirenz and amprenavir dosing.

The rationale for conducting ACTG 5043 in HIV-seronegative volunteer subjects was that stepwise introduction of a second PI to the combination of amprenavir plus efavirenz could be accomplished without the concern of drug concentrations being less than therapeutic, which might put HIV-in-

* Corresponding author. Mailing address: Adult ACTG Pharmacology Support Laboratory, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260. Phone: (716) 645-2828, ext. 252. Fax: (716) 645-2886. E-mail: emorse@buffalo.edu.

ected individuals at risk for the development of drug resistance.

MATERIALS AND METHODS

ACTG 5043 was an open-label, pharmacokinetic study of orally administered amprenavir 600 mg alone, followed by efavirenz 600 mg alone, followed in turn by the combination of amprenavir added to efavirenz, which was then continued with or without the administration of a second PI. The second PI was nelfinavir 1,250 mg every 12 h (q12h) (arm B), indinavir 1,200 mg q12h (arm C), ritonavir 100 mg q12h (arm D), or saquinavir soft gelatin capsules 1,600 mg q12h (arm E). The following pharmacokinetic studies were conducted on three days: a 24-hour study after the first dose of amprenavir, a 12-hour study after the attainment of steady state on efavirenz and amprenavir (day 14), and a 12-hour study after the attainment of steady state on the three-drug regimen (amprenavir plus efavirenz plus a second PI) on day 21. On each study day, intravenous catheters were placed to facilitate blood sampling. Study medications were ingested and blood samples were collected prior to and 1, 2, 3, 4, 5, 6, 8, 10, and 12 h after dosing (and 24 h after dosing on day 0).

Approximately 90 subjects were targeted to be enrolled in order to obtain 70 evaluable subjects with 14 per arm. Inclusion criteria were an age greater than or equal to 18 but less than or equal to 65 years, a body weight within 20 percent of ideal, a body weight of at least 50 kg, and HIV-1 seronegative status. Laboratory parameters were white blood cell counts $>4,000$ and <1.5 times the upper limit of normal (ULN), absolute neutrophil counts $>1,500$ cells/mm³ and <1.5 ULN, hemoglobin counts >11.7 and <16 g/dl for women and >12.7 and <18 g/dl for men, and $>100,000$ and $<450,000$ platelets/mm³. The following parameters also applied: fasting total cholesterol and triglyceride levels, <200 mg/dl; blood urea nitrogen level, $<1.25 \times$ ULN; creatinine level, less than ULN or corresponding to a calculated creatinine clearance of >80 ml/min; an albumin level within the normal limits for the testing laboratory; amylase level, less than the ULN; and, if elevated, a lipase level of less than the ULN and a pancreatic amylase level of less than the ULN. Total bilirubin, aspartate aminotransferase (serum glutamic oxalacetic transaminase), alanine aminotransferase (serum glutamic pyruvic transaminase), and alkaline phosphatase levels were $<1.25 \times$ ULN. Subjects had the ability and willingness to sign consent forms. Exclusion criteria included the following: reproductive potential (for women); ongoing cardiovascular, renal, hematologic, neurologic, gastrointestinal, pulmonary, psychiatric, endocrine, or immunologic disease or chronic ongoing gastrointestinal condition that might interfere with drug absorption; and any other medical condition which, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol. Subjects were not enrolled if they received protease inhibitors, NNRTIs, or investigational agents within 60 days prior to study entry or any acute therapy for an infection or other medical illness within 14 days prior to study entry. Healthy HIV-1 seronegative adult subjects who met the eligibility criteria signed a consent form. Subjects received their randomized study drug assignment (arms A through E) at the first pharmacokinetic study visit.

Antiretroviral assays. Efavirenz, nelfinavir, M8 (a primary metabolite of nelfinavir), amprenavir, indinavir, ritonavir, and saquinavir were measured by liquid chromatography with tandem mass spectrometry in the University at Buffalo ACTG Pharmacology Support Laboratory with a validated assay method (7, 12). The laboratory participates in the ACTG Pharmacology Laboratory Proficiency Testing Program for antiretroviral drug quantitation (11). Limits of detection were 16.3 ng/ml for amprenavir, indinavir, nelfinavir, and saquinavir, 51.2 ng/ml for ritonavir, and 8.19 ng/ml for M8. Interassay variations for all PI analytes measured $\leq 12\%$, $\leq 12\%$, $\leq 10\%$, and $\leq 8\%$ at ≤ 48 ng/ml, ≤ 240 ng/ml, $\leq 1,200$ ng/ml, and $\leq 6,000$ ng/ml, respectively. Efavirenz interassay variations were 7%, 7%, and 6% at 480 ng/ml, 1,200 ng/ml, and 2,400 ng/ml, respectively; the quantitation limit was set at 200 ng/ml.

Primary endpoints. The areas under the curve (AUCs) of amprenavir and efavirenz were the primary pharmacokinetic endpoints. The pharmacokinetic parameters of the maximum concentrations of the drugs in serum (C_{max}) and the concentrations of the drugs at 12 h (C_{12}) were also examined. Adverse reactions with severities of grade 1 or above (grade ≥ 1), as defined by the DAIDS toxicity tables, were monitored by the study team, and those that could not be directly attributed to a cause other than study treatment were identified as such. For each regimen within each treatment arm, the number of grade ≥ 1 rashes and the number of grade ≥ 2 reactions of other kinds were counted, as was the proportion of subjects evidencing such reactions. At the time of protocol development, concern about the possible occurrence of moderately severe rashes prompted the inclusion of the safety criterion that any subject developing a rash (not clearly attributable to a cause other than a study drug) was to be immediately discontinued from the study.

Pre-dose fasting biochemistry and endocrine evaluations were performed at all three pharmacokinetic study visits and at the final safety visit. These included measurements of glucose, insulin, C peptide, triglyceride, total cholesterol, and high-density lipoprotein cholesterol. At all three PK visits, glucose and insulin were also measured 2 h after the ingestion of the study medications and the protocol-specified breakfast. The lipid and endocrine data will be the subject of a separate report.

Statistical and pharmacokinetic analysis. Sample size calculations were based on a two-sided paired *t* test, with the type I error rate set to 5%, assuming a within-subject coefficient of variation (CV) in AUC of 20% for amprenavir. A sample size of 12 eligible subjects per arm provided 80% power to detect a 25% difference in AUCs (e.g., the percent change in the amprenavir AUCs without versus with the coadministration of a second PI). Accrual targets were set to 14 subjects per arm; the additional 2 subjects per arm were a buffer against adherence, sample, or assay problems not detected until after study closure. Only subjects who were able to provide pharmacokinetic data on all three study days were included in the statistical analysis of pharmacokinetic parameters. Throughout most of the study, subjects who discontinued early were replaced; due to slow accrual, however, a compromise between full accrual and provision of timely results was accepted, and accrual was closed before all targets were met. The final counts of subjects eligible for PK analysis on arms A through E were 11, 12, 13, 9, and 10, respectively, yielding detectable changes in APV AUCs ranging from 24% (arm C) to 29% (arm D).

A model-independent method was used to determine pharmacokinetic parameters using standard noncompartmental techniques (WinNonlin) based on individual subject concentration time profiles. In each arm, differences between APV and efavirenz (EFV) AUCs on days 21 and 14 were of primary interest and were evaluated using the nonparametric Wilcoxon signed-rank test. PK interactions were also evaluated using the Food and Drug Administration-recommended method for testing bioequivalence (3, 4). For each agent and pair of study days, the geometric mean of within-subject ratios was calculated along with the associated 90% confidence interval (CI). To compare AUCs across groups of subjects (those who did versus did not experience certain categories of toxicities or belong to certain racial/ethnic groups), the Wilcoxon rank sum and Kruskal-Wallis tests were used. Two-sided *P* values were considered throughout. As each arm was considered a separate experiment, no adjustments were made for multiple comparisons.

RESULTS

Subjects and tolerance of study medications. Eighty-five individuals were enrolled, of whom 82 received some study drug. Fifty-nine of these completed all three pharmacokinetic assessments; however, due to dosing errors, only 56 were included in pharmacokinetic analyses. Distributions by age, sex, and race were similar for the 56 subjects who were included in the pharmacokinetic analyses and for the 26 who were not. All but one were between 18 to 49 years old, and 54 of 56 were male.

The study medications were generally well tolerated; however, a wide variety of adverse events was reported, including a notable number of central nervous system effects, causing many subjects to be discontinued. Table 1 summarizes the toxicity data. Rash was not a major problem, with only nine subjects (11% of 82 receiving any medication) reporting the onset of rashes, all of which were of grade 1. Four rashes occurred during dosing with EFV alone (before a second dose of amprenavir was given), one occurred on day 5, and three occurred on day 9 or 10. However, median day 0 amprenavir AUCs were not significantly different between subjects with rashes and those without rashes. The remaining five rashes occurred 1 day into APV-plus-EFV dosing (two subjects), 1 day into APV-plus-EFV-plus-IDV dosing (one subject), 10 days into APV-plus-EFV-plus-SQV dosing (one subject), and 3 days after discontinuation of APV plus EFV plus IDV. Median day 14 efavirenz AUCs were significantly different between subjects with rashes and those without rashes (81.3 $\mu\text{g} \cdot$

TABLE 1. Proportions of subjects evidencing toxicities among those who had treatment dispensed and those with three evaluable pharmacokinetics studies

Toxicity	Proportion (%) of subjects evidencing toxicities in:					
	Control arm; APV+EFV	Arm B; APV+EFV+NFV	Arm C; APV+EFV+IDV	Arm D; APV+EFV+RTV	Arm E; APV+EFV+SQV	All arms combined
Grade ≥ 2 chemistry ^a in:						
Subjects receiving treatment	0/16 (0)	1/18 (6)	0/18 (0)	1/15 (7)	0/15 (0)	2/82 (2)
PK completers	0/11 (0)	0/12 (0)	0/13 (0)	1/10 (10)	0/10 (0)	1/56 (2)
Grade ≥ 1 rash in:						
Subjects receiving treatment	2/16 (13)	1/18 (6)	3/18 (17)	1/15 (7)	2/15 (13)	9/82 (11)
PK completers	0/11 (0)	0/12 (0)	2/13 (15)	0/10 (0)	0/10 (0)	2/56 (4)
Grade ≥ 2 CNS ^b in:						
Subjects receiving treatment	2/16 (13)	1/18 (6)	2/18 (11)	2/15 (13)	3/15 (20)	10/82 (12)
PK completers	0/11 (0)	0/12 (0)	0/13 (0)	2/10 (20)	0/10 (0)	2/56 (4)
Grade ≥ 2 signs/symptoms ^c in:						
Subjects receiving treatment	0/16 (0)	2/18 (11)	2/18 (11)	2/15 (13)	1/15 (7)	7/82 (9)
PK completers	0/11 (0)	2/12 (17)	1/13 (8)	1/10 (10)	1/10 (10)	5/56 (9)

^a There were no \geq grade 2 hematology adverse events.

^b One subject experienced a grade 3 CNS toxicity (excessive rage) after a single dose of amprenavir, at which time the site ascertained that the subject had prior depression that would interfere with his study participation. This subject was discontinued from study drug, was followed up for safety on day 25, and is excluded from the analysis presented here.

^c Excluding rash and CNS events.

h/ml [$n = 4$; range, 37.7 to 160.6] and 37.5 $\mu\text{g} \cdot \text{h/ml}$ [$n = 59$; range, 20.5 to 169.0], respectively; exact Wilcoxon rank sum P value = 0.035). Medications in subjects with rash (except for one case of topical irritation attributable to a cause other than a study drug) were promptly discontinued and the rashes resolved. Other side effects were uncommon, with two subjects experiencing clinical chemistry abnormalities. No hematologic abnormalities were observed. Of subjects who took any study drug, 23 of 79 males (29%) and 0 of 3 females (0%) experienced toxicities and/or discontinued early.

Among the 63 subjects for whom day 14 efavirenz AUCs were available, 12 subjects (19%) experienced no central nervous system (CNS) toxicities, 47 subjects (75%) experienced one or more CNS toxicities of grade 1, and 4 subjects (6%) experienced one or more CNS toxicities with maximums of grade 2. Median efavirenz AUCs in these three groups were 42.6, 37.7, and 36.7 $\mu\text{g} \cdot \text{h/ml}$, respectively. According to the Kruskal-Wallis (three groups) and exact two-sided Wilcoxon rank sum (no versus some toxicity) tests, there were no statistically significant differences in efavirenz AUCs between these groups ($P = 0.778$ and 0.883, respectively).

Pharmacokinetics. (i) Amprenavir. The pharmacokinetics of amprenavir, as illustrated by changes in AUC, are summarized in Tables 2 and 3. Figure 1 provides the median (25th to 75th percentile) amprenavir plasma concentrations on days 14 and 21 for each arm. After 13 days of efavirenz dosing, the median amprenavir AUC decreased an average of 52% across arms, ranging from 46% (arm A) to 61% (arm D). After 20 days of efavirenz coadministration, the median amprenavir AUC decreased 62% relative to that of amprenavir alone (no second PI; day 0). Compared with amprenavir AUCs on day 0, nelfinavir (arm B) led to a 107% median increase, indinavir (arm C) led to a 60% median increase, ritonavir (arm D) led to a 288% increase, and saquinavir (arm E) resulted in no significant change. Amprenavir AUCs were higher on day 21 than on

day 0 in 100%, 85%, and 100% of subjects in the nelfinavir, indinavir, and ritonavir arms, respectively. Relative to the amprenavir AUC after 14 days of efavirenz coadministration, the second protease inhibitor was associated with percentage changes in the amprenavir AUCs of -20.04 , $+315.74$, $+291.83$, $+888.40$, and $+17.56\%$ for no second PI, nelfinavir, indinavir, ritonavir, and saquinavir, respectively. Ninety-percent CIs around geometric mean ratios were as follows: 3.5 to 5.3 for nelfinavir ($P < 0.001$), 2.8 to 4.5 for indinavir ($P < 0.001$), and 7.8 to 11.5 for ritonavir ($P = 0.004$). The addition of saquinavir resulted in a change in the amprenavir AUC that was at the margin of statistical significance (GMR, 1.0 to 1.4; $P = 0.106$). AUCs in the control group were slightly lower on day 21 than on day 14 (Table 3).

(ii) Efavirenz. Ninety-percent CIs around the EFV geometric mean ratios (days 21 and 14) for arms A through E were as follows: 0.78 to 1.05, 0.91 to 1.06, 0.78 to 0.97, 0.82 to 1.08, and 0.80 to 0.97, respectively (Fig. 2).

(iii) Pharmacokinetics of second PI. The pharmacokinetics of the second PIs are summarized in Table 4. The median AUCs for nelfinavir, indinavir, ritonavir, and saquinavir were 26.46, 18.79, 3.21, and 2.81 $\mu\text{g} \cdot \text{h/ml}$, respectively. Median C_{max} values were 3.80, 5.95, 0.59, and 0.99 $\mu\text{g/ml}$, respectively. Median C_{12} values were 0.89, 0.04, 0.09, and 0.04, $\mu\text{g/ml}$, respectively. The ratio of the AUC of M8 to that of nelfinavir is described in Table 4.

Race/ethnicity relationships. Among 82 subjects who took any study drug, 61 were white non-Hispanic and 16 were African-American non-Hispanic. The remaining five subjects, of whom two were Hispanic and three were Asian/Pacific Islander, were not considered in the following analyses. There was no statistically significant association between race/ethnicity and day 0 amprenavir AUCs or between racial group and day 14 amprenavir AUCs. However, African-American non-Hispanics had significantly higher day 14 efavirenz AUCs than

TABLE 2. Amprenavir pharmacokinetics: summary statistics for amprenavir AUCs and C_{\max} and C_{12} values^a

Arm	PK parameter	Study day	Codrug(s)	No.	Mean	SD	CV (%)	Median	Range
A	AUC	0		11	9.23	3.97	43.0	8.87	3.61–15.01
		14	EFV	11	5.09	3.34	65.6	5.46	0.79–10.79
		21	EFV	11	3.94	2.08	52.7	4.37	0.51–7.51
	C_{\max}	0		11	2.61	1.19	45.6	2.59	0.96–5.33
		14	EFV	11	2.20	1.64	74.9	2.26	0.41–5.19
		21	EFV	11	1.59	0.88	55.4	1.82	0.22–3.09
	C_{12}	0		11	0.14	0.11	73.0	0.11	0.05–0.38
		14	EFV	8	0.06	0.03	54.3	0.05	0.03–0.12
		21	EFV	9	0.04	0.03	72.5	0.03	0.02–0.11
B	AUC	0		12	7.20	3.65	50.7	7.06	2.43–15.90
		14	EFV	12	3.82	2.13	55.6	3.30	1.26–8.97
		21	EFV+NFV	12	15.89	7.18	45.2	14.06	6.65–31.14
	C_{\max}	0		12	2.28	1.00	43.9	2.06	0.73–4.16
		14	EFV	12	1.55	0.79	50.7	1.54	0.43–3.51
		21	EFV+NFV	12	2.76	0.97	35.0	2.65	1.30–4.60
	C_{12}	0		11	0.14	0.13	90.4	0.09	0.03–0.49
		14	EFV	9	0.06	0.03	46.1	0.05	0.03–0.11
		21	EFV+NFV	12	0.42	0.34	81.6	0.32	0.06–1.18
C	AUC	0		13	9.11	6.08	66.7	7.91	2.08–23.62
		14	EFV	13	4.80	3.58	74.7	4.48	0.82–13.47
		21	EFV+IDV	13	14.88	8.42	56.6	14.20	3.98–31.65
	C_{\max}	0		13	2.39	1.19	49.5	2.12	0.85–4.59
		14	EFV	13	1.63	1.00	61.3	1.46	0.47–3.51
		21	EFV+IDV	13	3.54	1.47	41.6	3.22	1.18–6.51
	C_{12}	0		13	0.16	0.13	85.4	0.09	0.04–0.49
		14	EFV	9	0.05	0.06	117.4	0.03	0.02–0.20
		21	EFV+IDV	12	0.12	0.09	81.3	0.10	0.02–0.35
D	AUC	0		9	9.59	4.13	43.1	10.27	1.92–14.13
		14	EFV	9	3.56	1.39	39.0	4.11	1.59–5.71
		21	EFV+RTV	9	32.86	11.49	35.0	32.46	16.70–55.98
	C_{\max}	0		9	2.70	1.29	47.9	2.84	0.50–4.67
		14	EFV	9	1.48	0.70	47.0	1.47	0.50–2.22
		21	EFV+RTV	9	4.25	1.41	33.1	4.00	2.53–7.42
	C_{12}	0		9	0.14	0.09	66.4	0.12	0.03–0.31
		14	EFV	6	0.03	0.01	24.0	0.03	0.03–0.05
		21	EFV+RTV	9	1.72	0.68	39.8	1.32	1.04–2.85
E	AUC	0		10	7.26	2.81	38.8	6.92	3.93–10.82
		14	EFV	10	3.52	1.43	40.6	3.80	1.50–5.82
		21	EFV+SQV	10	4.40	2.43	55.3	4.61	1.91–10.17
	C_{\max}	0		10	2.16	1.01	46.9	1.77	1.05–4.34
		14	EFV	10	1.56	0.75	48.3	1.51	0.63–3.00
		21	EFV+SQV	10	1.55	0.95	61.3	1.29	0.68–3.73
	C_{12}	0		10	0.10	0.06	60.0	0.09	0.03–0.23
		14	EFV	7	0.04	0.03	72.7	0.03	0.01–0.09
		21	EFV+SQV	7	0.04	0.03	77.9	0.03	0.01–0.11

^a AUCs in $\mu\text{g} \cdot \text{h/ml}$; C_{\max} and C_{12} values in $\mu\text{g/ml}$.

white non-Hispanics: the median efavirenz AUCs were 49.0 and 37.6 $\mu\text{g} \cdot \text{h/ml}$, respectively (exact two-sided Wilcoxon rank sum P value = 0.025), as shown in Fig. 3.

DISCUSSION

At the time ACTG 5043 was conducted, the routine use of low-dose ritonavir was uncommon, but the desire to optimize individual protease inhibitor pharmacokinetics was under active investigation. The use of efavirenz combined with PIs was also under investigation in clinical trials for patients failing PI therapy (6, 9, 10). In addition, the need for salvage therapy protocols often preceded the availability of intensive three-way drug interaction studies, and it was common to include phar-

macokinetic substudies as means of determining complex interactions. In contrast, conducting pharmacokinetic studies in seronegative subjects may provide an opportunity to examine three-way drug interactions without the potential for the development of resistance. On the other hand, the data from this type of study design may not be directly applicable to HIV-infected patients who have coinfective hepatitis B and/or C due to altered metabolic capacities.

Safety and tolerability. Pharmacokinetic studies of antiretroviral agents in HIV-seronegative subjects have merit because short durations and sequential additions of antiretroviral medications can be evaluated without concern for the development of drug-resistant virus in HIV-infected individuals. Further,

TABLE 3. Comparison of amprenavir AUCs in each arm

Arm	Comparison of	Median percent change	90% CI around GMR	Wilcoxon signed-rank <i>P</i> value	Paired <i>t</i> test <i>P</i> value
A	Day 14 to day 0	-46.21	0.34, 0.65	0.0020	0.0016
	Day 21 to day 14	-20.04	0.69, 0.97	0.0420	0.0690
	Day 21 to day 0	-61.75	0.27, 0.53	0.0010	0.0004
B	Day 14 to day 0	-48.42	0.44, 0.63	0.0005	0.0002
	Day 21 to day 14	315.74	3.52, 5.27	0.0005	≤0.0001
	Day 21 to day 0	107.17	1.66, 3.12	0.0005	0.0014
C	Day 14 to day 0	-53.11	0.35, 0.66	0.0017	0.0034
	Day 21 to day 14	291.83	2.83, 4.47	0.0002	≤0.0001
	Day 21 to day 0	59.65	1.24, 2.36	0.0017	0.0037
D	Day 14 to day 0	-61.34	0.31, 0.50	0.0039	0.0005
	Day 21 to day 14	888.40	7.83, 11.47	0.0039	≤0.0001
	Day 21 to day 0	287.78	2.73, 5.07	0.0039	0.0001
E	Day 14 to day 0	-51.05	0.32, 0.71	0.0059	0.0059
	Day 21 to day 14	17.56	1.00, 1.45	0.1055	0.1509
	Day 21 to day 0	-42.69	0.37, 0.89	0.0645	0.0540

the influence of concurrent viral infection on toxicity assessment is eliminated. However, previous studies of amprenavir pharmacokinetics in HIV-seronegative subjects showed frequent rashes, including grade 3 rashes (27). In contrast, other studies in healthy volunteers and clinical studies with amprenavir in HIV-infected patients indicate that the drug is well tolerated when administered for long periods of time, although cutaneous reactions were the most common adverse experiences reported by clinical investigators as possibly due to amprenavir. There was an overall incidence of rash in 19% of subjects enrolled in phase II/III trials (20, 21, 23, 24, 26). We found an overall rash rate of 11% in A5043, and none of the rashes were greater than grade 1. We noted no relationship between rash occurrence and amprenavir plasma concentrations, but we noted higher EFV concentrations in subjects exhibiting rash.

In our study, efavirenz concentrations did not correlate with CNS symptoms, possibly because subjects with more-severe CNS toxicities dropped out before the efavirenz AUCs were obtained on day 14. This conjecture is supported by the fact that efavirenz AUCs were available for 93% (13/14) of those without CNS toxicities, 85% (47/55) of those with CNS toxicities of grade 1, and only 40% (4/10) of those with one or more CNS toxicities of grade 2.

Drug interaction pharmacokinetics. ACTG 5043 confirmed the previously reported low plasma concentrations of amprenavir that are observed during the latter portion of a 12-hour dosing period secondary to the induction effects of efavirenz on amprenavir (5, 6, 14). Prior studies indicate that induction and inhibition are mediated by cytochrome P4503A4 effects (16–19). Consistent with previous reports, A5043 found that a low dose of ritonavir could overcome the efavirenz induction effects (14). Interestingly, the additions of other PIs had variable effects on the amprenavir AUC in the presence of efavirenz. When saquinavir was the second PI, this increase was not sufficient to compensate for induction by efavirenz; however, with the other three PIs, amprenavir concentrations were increased markedly over those seen with amprenavir

alone. Consistent with the elevated levels of amprenavir seen in the A5043 subjects with indinavir and nelfinavir added to their amprenavir and efavirenz, prior pharmacokinetic studies at weeks 2 and 24 noted that intrinsic clearance of amprenavir was reduced by 41% and 54% by nelfinavir and indinavir, respectively (13). In a prior study of dual PIs with efavirenz in salvage regimens (ACTG 398), saquinavir had a minimal effect on amprenavir clearance, similar to the results of the present study. Amprenavir clearance was noted to increase by more than 30% from week 2 to week 24. The mechanism for this long-term change in exposure remains unclear but may be partially due to additional enzyme induction after the antiviral activity of a regimen has been maximized. This may also explain why the APV concentrations were lower on day 21 than on day 14 in the absence of a second PI. We have recently reported a similar finding for the effect of efavirenz on nelfinavir over a 32-week period (25).

In a prior study of salvage regimens containing efavirenz, amprenavir, and a second PI (indinavir, nelfinavir, or saquinavir), a ~30% success rate was reported (10). It is possible that the use of higher initial doses, optimal drug combinations that enhance PI levels, or therapeutic drug monitoring allowing higher doses in some patients would have resulted in improved clinical responses.

The effect of ritonavir in countering efavirenz induction has been previously described (2, 14, 15), and the A5043 data are consistent with these findings. In addition, Wire et al. reported an interaction among fosamprenavir, ritonavir, and efavirenz. Amprenavir exposure was not reduced when efavirenz was added to fosamprenavir (700 mg twice a day [BID]) with ritonavir (100 mg BID). However, amprenavir exposure was reduced when efavirenz was added to fosamprenavir (1,400 mg once a day) with ritonavir (100 mg once a day). Because lower plasma amprenavir trough concentrations are observed with the regimen of one daily dose, these results suggest that plasma ritonavir concentrations must be maintained at levels necessary to counteract the induction effects of efavirenz. Given the rapid and nearly complete conversion of fosamprenavir to am-




FIG. 1. Arm-specific amprenavir concentrations by sample time when amprenavir is coadministered with EFV and with EFV plus a second PI. For each arm separately, median amprenavir concentrations are plotted against (offset) scheduled sample times when subjects had taken APV plus EFV only (day 14) and when subjects had taken APV plus EFV and (on all but arm A) a second protease inhibitor (day 21). Error bars indicate the 25th and 75th percentiles of amprenavir concentrations. So that the day 14 and 21 points can be distinguished, they are offset slightly to the left and right, respectively.

prenavir in vivo and the similarity of metabolic drug interaction data, drug interaction data from amprenavir may be reasonably applied to fosamprenavir (28).

In a prior study (ACTG 398), nelfinavir and indinavir increased plasma amprenavir exposure to similar extents, whereas saquinavir was associated with an increase of marginal significance. The “pharmacokinetic-enhancing” effects of nelfinavir and indinavir on plasma amprenavir exposure (in combination with efavirenz) also appeared to be greater in the present study (~200% versus 300%). Several factors associated with A5043 may account for the apparent greater magni-

tude of boosting, such as the shorter duration of amprenavir dosing in combination with the second PI (7 days versus 14 days), the lower amprenavir dose (600 mg BID versus 1,200 mg BID), the use of uninfected subjects, and the use of intrasubject comparisons. It is interesting that an increased amprenavir exposure in A5043 was also observed in combination with nelfinavir and indinavir (both in combination with efavirenz) as in a prior report (ACTG 398). With regard to the plasma pharmacokinetic parameters for the second PI in A5043, values appeared to be within the range reported in other studies.

Similar to what has been seen in other reports, none of the




FIG. 2. Efavirenz bioequivalence results for each arm showing the geometric mean of within-subject ratios (EFV AUC with APV + a second PI/EFV AUC with APV only; days 21 and 14) and the associated 90% confidence intervals. Lower and upper dashed lines represent the no-effect boundaries of 80% to 125%. Reference lines for 62.5% and 160.0% are also shown.

various A5043 study arms appeared to have significant effects on plasma efavirenz exposure; however, efavirenz concentrations were higher in African-Americans. Higher plasma concentrations and increased CNS toxicity from efavirenz have been observed in African-Americans in recent clinical studies (22). These increased concentrations are thought to result from altered efavirenz metabolism. Polymorphisms in CYP 2B6, more common in African-Americans, result in reduced metabolism of efavirenz with consequent higher plasma concentrations (2, 8). This should be considered when EFV is prescribed for African-Americans.

In considering the possible mechanisms that may be underlying these three-way interactions, it is likely that efavirenz induces CYP4503A induction in hepatocytes (and possibly intestinal endothelial cells), which accounts for the lower plasma concentrations of amprenavir following coadministration with efavirenz. If this is the case, then the addition of a 3A4 inhib-

itor would be expected to counter, to some degree, the greater metabolic capacity induced by efavirenz. This was the case for each of the protease inhibitors (except saquinavir) as follows: for indinavir to a lesser extent than for nelfinavir, and for nelfinavir to a lesser extent than for ritonavir. Although nelfinavir and indinavir provide increases in plasma amprenavir exposure, they are not as potent as low-dose ritonavir. However, full doses of these agents would be expected to provide additional virologic activity, whereas low-dose ritonavir does not.

In summary, there still exists some uncertainty as to whether the incidence of amprenavir-associated rash among HIV-seronegative volunteers is a significant barrier to conducting mechanistic studies. Observations from some studies suggest that prior exposure to ritonavir or lopinavir-ritonavir seems to reduce the occurrence of amprenavir-associated rash (27). A similar finding when investigating delavirdine with ritonavir

TABLE 4. Pharmacokinetics of second protease inhibitors: summary statistics for AUCs, for C_{max} and C_{12} values, and for the ratio of AUCs for M8 and NFV^a

Analyte	Parameter	No.	Mean	SD	CV (%)	Median	Range
NFV	AUC	12	31.13	12.83	41.2	26.46	18.40–65.46
	C_{max}	12	4.34	1.45	33.4	3.80	2.95–7.95
	C_{12}	12	1.11	0.81	72.9	0.89	0.37–3.33
M8	AUC	12	5.72	2.95	51.7	5.86	1.10–11.02
	C_{max}	12	0.88	0.36	41.3	0.86	0.24–1.53
	C_{12}	12	0.16	0.13	81.9	0.12	0.01–0.44
M8:NFV	AUC	12	0.19	0.09	46.7	0.17	0.05–0.33
IDV	AUC	13	19.57	6.75	34.5	18.79	8.76–34.37
	C_{max}	13	6.77	2.40	35.5	5.95	3.27–11.30
	C_{12}	13	0.05	0.03	55.5	0.04	0.02–0.11
RTV	AUC	10	3.22	1.11	34.5	3.21	1.46–5.37
	C_{max}	10	0.63	0.26	41.9	0.59	0.31–1.09
	C_{12}	9	0.10	0.06	62.8	0.09	0.03–0.24
SQV	AUC	10	3.19	1.60	50.0	2.81	1.23–7.23
	C_{max}	10	1.01	0.46	45.7	0.99	0.44–2.09
	C_{12}	10	0.04	0.03	69.2	0.04	0.02–0.12

^a AUCs in $\mu\text{g} \cdot \text{h/ml}$; C_{max} and C_{12} values in $\mu\text{g/ml}$.




FIG. 3. Box plot of day 14 efavirenz AUCs in white non-Hispanic and black non-Hispanic subjects. The height of each box represents the interquartile range (the distance between the 25th and the 75th percentiles), the horizontal lines in the box interiors represent the medians, and the vertical lines issuing from the boxes extend to the most extreme data points that are within 1.5 times the interquartile ranges of the boxes. The circles represent points outside these ranges.

was observed (25), suggesting that an intermediate metabolite may mediate the hypersensitivity. This remains an important area of clinical investigation, since new interactions with fosamprenavir will require in-depth drug interaction studies, especially in dual-PI regimens with ritonavir pharmacokinetic enhancement. Conducting this three-way interaction study in seronegative volunteers was a safe and ethical alternative to studying HIV-infected patients and allowed a more robust study methodology to investigate these complex interactions by a crossover (within-subject) design. These data indicate that PI dosing may not be readily predicted from *in vitro* inhibition data and that clinical pharmacokinetic studies are required when dual PIs are combined with an inducing NNRTI, such as efavirenz.

ACKNOWLEDGMENTS

The participation of the study volunteers in helping to answer the clinical research questions in A5043 is appreciated. The research staff at the following Adult ACTG units and general clinical research centers participated in A5043: the AIDS clinical trial units of Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Colorado, University of Rochester, University of Washington, Vanderbilt University, Washington University, Adult ACTG Pharmacology Support Laboratory—University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Barbara Brizz is at the ACTG Operation Center, Yoninah Segal is Clinical Trials Specialist at the Statistical Data Analysis Center, Ann Walawander and Courtney Ashton are at the Data Management Center, and Elaine Ferguson is at DAIDS. Pharmaceutical company representatives were Pascal J. de Caprariis (Roche), Alfred J. Saah (Merck), Mark Becker (Agouron), and Mary Wire and Mark Shelton (GlaxoSmithKline).

Support was provided by the General Clinical Research Center (GCRC) of the National Center of Research Resources of the NIH and by the following grants to the ACTG ACTUs: for University at Buffalo, ACTG PSL grant AI-38858; for Johns Hopkins University, ACTU grant AI-27668 and GCRG grant RR-00052; for Rochester, ACTU grant AI-27658 and GCRC grant RR00044; for Ohio State, ACTU grant 5U01AI025924 and GCRC grant M01-RR00034; for University of Washington, ACTU grant AI27664 and GCRC grant M01-RR-00037; for Washington University, ACTU grant AI 25903-15 and GCRC grant MO1-RR00036; for Stanford University, ACTU grant AI27666 and GCRC grant M01-RR00070; for Indiana University, ACTU grant UO1 AI025859-18 and GCRC grant MO1RR00750; and for University of Colorado Health Sciences Center, ACTU grant AI 32770 and GCRC grant M01 RR00051-43.

REFERENCES

1. AIDSinfo, U.S. Department of Health and Human Services. 2004. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Online.] http://aidsinfo.nih.gov/guidelines/adult/archives/AA_032304.pdf.
2. Barrett, J. S., A. S. Joshi, M. Chai, T. M. Ludden, W. D. Fiske, and H. J. Pieniaszek, Jr. 2002. Population pharmacokinetic meta-analysis with efavirenz. *Int. J. Clin. Pharmacol. Ther.* **40**:507–519.
3. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. 1999. FDA guidance for industry. *In vivo* drug metabolism/drug interaction studies—study design, data analysis and recommendations for dosing and labeling.
4. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. 2001. Statistical approaches to establishing bioequivalence.
5. Duval, X., V. Le Moing, C. Longuet, C. Lepout, J. L. Vilde, C. Lamotte, G. Peytavin, and R. Farinotti. 2000. Efavirenz-induced decrease in plasma amprevir levels in human immunodeficiency virus-infected patients and correction by ritonavir. *Antimicrob. Agents Chemother.* **44**:2593.
6. Falloon, J., S. Piscitelli, S. Vogel, B. Sadler, H. Mitsuya, M. F. Kavlick, K. Yoshimura, M. Rogers, S. LaFon, D. J. Manion, H. C. Lane, and H. Masur. 2000. Combination therapy with amprevir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. *Clin. Infect. Dis.* **30**:313–318.
7. Frerichs, V. A., R. DiFrancesco, and G. D. Morse. 2003. Determination of protease inhibitors using liquid chromatography coupled to tandem mass spectrometry. *J. Chromatogr. B* **787**:393–403.
8. Haas, D. W., H. Ribaud, R. B. Kim, C. Tierney, G. R. Wilkinson, R. Gulick, D. Clifford, T. Hulgan, and E. P. Acosta. 2004. A common *CYP2B6* variant is associated with efavirenz (EFV) pharmacokinetics (PK) and central nervous system (CNS) side effects: AACTG study NWCS214. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif.
9. Hammer, S. M., R. Bassett, K. E. Squires, M. A. Fischl, L. M. Demeter, J. S. Currier, J. W. Mellors, G. D. Morse, J. J. Eron, J. L. Santana, and V. DeGruttola for the ACTG 372B/D Study Team. 2003. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1 infected persons with virologic failure receiving indinavir. *Antivir. Ther.* **8**:507–518.
10. Hammer, S. M., F. Vaida, K. K. Bennett, M. K. Holohan, L. Sheiner, J. J. Eron, L. J. Wheat, R. T. Mitsuyasu, R. M. Gulick, F. T. Valentine, J. A. Aberg, M. D. Rogers, C. N. Karol, A. J. Saah, R. H. Lewis, L. J. Bessen, C. Brosgart, V. DeGruttola, J. W. Mellors, and the AIDS Clinical Trials Group 398 Study Team. 2002. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. *JAMA* **288**:169–180.
11. Holland, D. T., R. DiFrancesco, J. Stone, F. Hamzeh, J. D. Connor, and G. D. Morse. 2004. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. *Antimicrob. Agents Chemother.* **48**:824–831.
12. Pfister, L., L. Labbé, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, L. B. Sheiner, and the AIDS Clinical Trial Group Protocol 398 Investigators. 2003. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group study 398. *Antimicrob. Agents Chemother.* **47**:130–137.
13. Piscitelli, S., S. Vogel, et al. 1998. Effect of efavirenz (DMP-266) on the pharmacokinetics of 141W94 in HIV infected patients. *Abstr. Fifth Conference on Retroviruses and Opportunistic Infections*, Chicago, Ill., February 1–5, abstr. 346.
14. Piscitelli, S., C. Bechtel, B. Sadler, et al. 2000. The addition of a second protease inhibitor eliminates amprevir-efavirenz drug interaction and increases plasma amprevir concentrations. *Abstr. Seventh Conference on Retroviruses and Opportunistic Infections*, San Francisco, Calif., January 31–February 2, abstr. 78.
15. Polk, R. E., D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein. 2001. Pharmacokinetic interaction between amprevir and rifabutin or rifampin in healthy males. *Antimicrob. Agents Chemother.* **45**:502–508.
16. Polk, R. E., M. A. Crouch, D. S. Israel, A. Pastor, B. M. Sadler, G. E. Chittick, W. T. Symonds, W. Gouldin, and Y. Lou. 1999. Pharmacokinetic interaction between ketoconazole and amprevir after single doses in healthy men. *Pharmacotherapy* **19**:1378–1384.
17. Polk, R. E., D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein. 2001. Pharmacokinetic interaction between amprevir and rifabutin or rifampin in healthy males. *Antimicrob. Agents Chemother.* **45**:502–508.
18. Polk, R. E., M. A. Crouch, D. S. Israel, A. Pastor, B. M. Sadler, G. E. Chittick, W. T. Symonds, W. Gouldin, and Y. Lou. 1999. Pharmacokinetic interaction between ketoconazole and amprevir after single doses in healthy men. *Pharmacotherapy* **19**:1378–1384.
19. Ribaud, H., D. Clifford, R. Gulick, C. Shikuma, K. Klingman, S. Snyder, and E. Acosta. 2004. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTGA5095/A5097s. *Abstr. Eleventh Conference on Retroviruses and Opportunistic Infections*, San Francisco, Calif., abstr. 132.
20. Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprevir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. *Antimicrob. Agents Chemother.* **43**:1686–1692.
21. Sadler, B., C. Gillotin, G. E. Chittick, et al. 1998. Pharmacokinetic drug interactions with amprevir. 12th World AIDS Conference, Geneva, Switzerland, abstr. 12389.
22. Sadler, B. M., C. Gillotin, Y. Lou, J. J. Eron, W. Lang, R. Haubrich, and D. S. Stein. 2001. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprevir. *Antimicrob. Agents Chemother.* **45**:3663–3668.
23. Sadler, B. M., J. Eron, J. Waford, et al. 1997. Pharmacokinetics of amprevir and indinavir after single dose administration in HIV-positive volunteers. *Program Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother.*, abstr. A-56.
24. Sadler, B. M., P. J. Piliero, S. L. Preston, P. P. Lloyd, Y. Lou, and D. S. Stein. 2001. Pharmacokinetics and safety of amprevir and ritonavir following multiple-dose coadministration to healthy volunteers. *AIDS* **15**:1009–1018.

25. **Shelton, M. J., R. G. Hewitt, J. Adams, A. Della-Coletta, S. Cox, and G. D. Morse.** 2003. Inhibition of ritonavir metabolism by delavirdine mesylate in HIV-infected patients. *Antimicrob. Agents Chemother.* **47**:1694–1699.
26. **Smith, P. F., G. Robbins, R. Shafer, H. Wu, S. Yu, M. Hirsch, T. Merigan, G. D. Morse, and the ACTG 384 Study Team.** 2003. Effect of efavirenz on the pharmacokinetics of nelfinavir (NFV) and M8 in naïve, HIV-infected patients receiving long-term HAART therapy. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Mass., paper 147, session 28.
27. **Williams, L., R. Odeh, M. Weinberg, et al.** 2000. High incidence of rash associated with amprenavir (APV) during a pharmacokinetic (PK) interaction trial in HIV-negative, healthy volunteers. Abstr. 13th International AIDS Conference, Durban, South Africa, July 9–14, abstr. 2.6.
28. **Wire, M. B., C. Ballou, S. L. Preston, C. W. Hendrix, P. J. Piliero, Y. Lou, and D. S. Stein.** 2004. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. *AIDS* **18**:897–907.
29. **Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding.** 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. *JAMA* **292**:251–265.